Crunch Time For Cytokinetics As Aficamtem Readout Approaches
Executive Summary
The takeover target will present eagerly anticipated Phase III data on the cardiac myosin inhibitor for obstructive hypertrophic cardiomyopathy before the end of the year and potential suitors are preparing to pounce, according to the rumor mill.